Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT00886691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase II trial studies how well bevacizumab with or without everolimus works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and everolimus may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with or without everolimus in treating ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Study identification
- NCT ID
- NCT00886691
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Biological
- Everolimus Drug
- Laboratory Biomarker Analysis Other
- Placebo Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2010 (Actual)
- Primary completion
- Jun 27, 2014 (Actual)
- Completion
- Mar 23, 2015 (Actual)
- Last update posted
- Feb 4, 2022
2010 – 2015
United States locations
- U.S. sites
- 45
- U.S. states
- 22
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Gynecologic Oncology Group of Arizona | Phoenix | Arizona | 85012 | — |
| Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank | California | 91505 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06050 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Sudarshan K Sharma MD Limited-Gynecologic Oncology | Hinsdale | Illinois | 60521 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Saint Vincent Hospital and Health Care Center | Indianapolis | Indiana | 46260 | — |
| McFarland Clinic PC - Ames | Ames | Iowa | 50010 | — |
| Iowa Methodist Medical Center | Des Moines | Iowa | 50309 | — |
| Iowa-Wide Oncology Research Coalition NCORP | Des Moines | Iowa | 50309 | — |
| Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa | 50309 | — |
| Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa | 50314 | — |
| Mercy Medical Center - Des Moines | Des Moines | Iowa | 50314 | — |
| Iowa Lutheran Hospital | Des Moines | Iowa | 50316 | — |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Baystate Medical Center | Springfield | Massachusetts | 01199 | — |
| Saint Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Mercy Hospital Springfield | Springfield | Missouri | 65804 | — |
| CoxHealth South Hospital | Springfield | Missouri | 65807 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Carolinas Medical Center/Levine Cancer Institute | Charlotte | North Carolina | 28203 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Riverside Methodist Hospital | Columbus | Ohio | 43214 | — |
| Hillcrest Hospital Cancer Center | Mayfield Heights | Ohio | 44124 | — |
| UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor | Ohio | 44060 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa | Oklahoma | 74146 | — |
| Jefferson Abington Hospital | Abington | Pennsylvania | 19001 | — |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Reading Hospital | West Reading | Pennsylvania | 19611 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| AnMed Health Cancer Center | Anderson | South Carolina | 29621 | — |
| Baylor All Saints Medical Center at Fort Worth | Fort Worth | Texas | 76104 | — |
| LDS Hospital | Salt Lake City | Utah | 84143 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00886691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2022 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00886691 live on ClinicalTrials.gov.